HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) had its target price lowered by HC Wainwright from $22.00 to $12.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

YMAB has been the subject of several other reports. Wedbush reaffirmed an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a "buy" rating and a $17.00 price target for the company. Bank of America dropped their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial dropped their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $18.30.

Remove Ads

Y-mAbs Therapeutics Stock Down 1.4 %

Y-mAbs Therapeutics stock traded down $0.07 during mid-day trading on Friday, reaching $5.09. 234,261 shares of the company's stock traded hands, compared to its average volume of 329,302. Y-mAbs Therapeutics has a 12-month low of $4.25 and a 12-month high of $17.78. The stock has a 50 day moving average of $5.66 and a two-hundred day moving average of $9.65. The company has a market cap of $230.16 million, a price-to-earnings ratio of -9.43 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to analysts' expectations of $26.70 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in YMAB. Infinitum Asset Management LLC purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth about $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Y-mAbs Therapeutics by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock valued at $410,000 after purchasing an additional 7,765 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Y-mAbs Therapeutics by 31.6% in the 4th quarter. Two Sigma Investments LP now owns 88,337 shares of the company's stock worth $692,000 after purchasing an additional 21,196 shares during the period. Rafferty Asset Management LLC lifted its position in shares of Y-mAbs Therapeutics by 17.6% in the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company's stock worth $323,000 after purchasing an additional 6,178 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $99,000. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.